Amro Albanna - Aditxt Chairman CoFounder
| ADTX Stock | USD 0.32 0.02 5.88% |
Insider
Amro Albanna is Chairman CoFounder of Aditxt Inc
| Age | 54 |
| Address | 737 North Fifth Street, Richmond, VA, United States, 23219 |
| Phone | 650 870 1200 |
| Web | https://www.aditxt.com |
Amro Albanna Latest Insider Activity
Tracking and analyzing the buying and selling activities of Amro Albanna against Aditxt stock is an integral part of due diligence when investing in Aditxt. Amro Albanna insider activity provides valuable insight into whether Aditxt is net buyers or sellers over its current business cycle. Note, Aditxt insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aditxt'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Amro Albanna over a year ago Acquisition by Amro Albanna of 9404 shares of Aditxt subject to Rule 16b-3 | ||
Amro Albanna over a year ago Purchase by Amro Albanna of 500 shares of Aditxt |
Aditxt Management Efficiency
The company has return on total asset (ROA) of (1.1761) % which means that it has lost $1.1761 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.9363) %, meaning that it created substantial loss on money invested by shareholders. Aditxt's management efficiency ratios could be used to measure how well Aditxt manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.76 in 2024. Return On Capital Employed is likely to rise to -1.32 in 2024. At this time, Aditxt's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 39.5 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 3.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| James Rolke | Revelation Biosciences | 55 | |
| James JD | Allarity Therapeutics | 55 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| David Hale | Dermata Therapeutics | 75 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Ben MD | Neurobo Pharmaceuticals | 68 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Robert McRae | Palisade Bio | N/A | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Carol Odle | Revelation Biosciences | N/A | |
| Professor MD | Allarity Therapeutics | 67 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Chester III | Revelation Biosciences | 44 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Andrew Sims | Plus Therapeutics | 50 | |
| John Fraser | Plus Therapeutics | 63 | |
| MS MBA | Plus Therapeutics | N/A | |
| Marc MD | Plus Therapeutics | 61 | |
| FACNP FACP | Plus Therapeutics | 74 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
Management Performance
| Return On Equity | -34.94 | ||||
| Return On Asset | -1.18 |
Aditxt Inc Leadership Team
Elected by the shareholders, the Aditxt's board of directors comprises two types of representatives: Aditxt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aditxt. The board's role is to monitor Aditxt's management team and ensure that shareholders' interests are well served. Aditxt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aditxt's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, President | ||
| Jennifer Lee, Director Resources | ||
| Thomas CPA, Chief Officer | ||
| Matthew Shatzkes, Chief Counsel | ||
| MS MD, Senior Discovery | ||
| Dr D, Senior Transplantation | ||
| Amro Albanna, Chairman CoFounder | ||
| Dolly Tyan, Senior Transplantation | ||
| Rowena Albanna, Chief Officer | ||
| DDS MS, Chief CoFounder |
Aditxt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aditxt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -34.94 | ||||
| Return On Asset | -1.18 | ||||
| Operating Margin | (134.97) % | ||||
| Current Valuation | 12.62 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.25 % | ||||
| Number Of Shares Shorted | 910.84 K | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 8.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Aditxt Stock Analysis
When running Aditxt's price analysis, check to measure Aditxt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aditxt is operating at the current time. Most of Aditxt's value examination focuses on studying past and present price action to predict the probability of Aditxt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aditxt's price. Additionally, you may evaluate how the addition of Aditxt to your portfolios can decrease your overall portfolio volatility.